Cell and gene therapies
-
NZ looks to make cheaper CAR-T
- 08 Oct 2021
A Chinese partnership and US funding deal are enabling NZ to enact a vision to provide CAR-T to thousands of Kiwis at a much lower price.
Read more -
Janssen CAR-T lands in Australia
- 27 Sep 2021
First of a new class of anti-BCMA therapies kicks off its HTA journey with an MSAC sub-committee appearance later this year.
Read more -
Novartis ‘game changer’ heart shot MIA
- 17 Sep 2021
Company gives an update on access plans following the registration of its bi-annual anti-cholesterol shot, and progress on a gene therapy.
Read more -
Genomics chair sounds warning bell
- 01 Sep 2021
Australian policymakers need to act fast to stay ahead of the social conversation, says InGeNA’s David Bunker.
Read more -
Third CAR-T gets TGA tick
- 06 Aug 2021
Gilead’s Tecartus registered in Australia, setting it up for faster funded access as Australia spends $100m on CAR-Ts in 2021-22.
Read more -
England launches $635m new drug fund
- 23 Jul 2021
NHS ‘ringfences’ $1.27 billion for new drugs including gene therapies, adding an Innovative Medicines Fund to its Cancer Drugs Fund.
Read more -
Cell and gene ‘roadmap’ launched
- 22 Jul 2021
Commissioned by Novartis, this new report shines a light on the way forward for Australians to access these next-gen therapies.
Read more -
Local CF patients in gene therapy trial
- 09 Jul 2021
Up to 15 Aussie adults with cystic fibrosis will be the first in the world to trial a new gene therapy developed in the US.
Read more